News

The U.S. Food and Drug Administration will allow MonoSol Rx to use a new form of its Riluzole therapy, Riluzole Oral Soluble Film (Riluzole OSF), to treat amyotrophic lateral sclerosis (ALS) before the agency approves the new therapy. The FDA granted MonoSol Rx’s request that Riluzole OSF receive Investigational New Drug status, which…

AB Science SA‘s anti-inflammation treatment masitinib protects muscles and nerves against damage from amyotrophic lateral sclerosis (ALS), researchers have concluded. Professor Luis Barbeito of the Institut Pasteur in Montevideo, Uruguay, presented the findings at the 27th International Symposium on ALS/MND (Motor Neuron Disease) in Dublin, Ireland, in December of 2016. Masitinib…

By inserting gene coding for light-sensitive proteins into other cells, researchers have developed a tool for studying the way liquid-like protein structures assemble inside cells. The tool will not only increase understanding of how cells work while healthy, but also contribute to research on diseases such as amyotrophic lateral sclerosis…

The pharmaceutical companies Evotec and Celgene will collaborate on a drug discovery and development program to identify and develop novel disease-modifying therapies for several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). The partnership will allow the screening of drug compounds developed by Celgene using Evotec’s platform of induced pluripotent…

Patients with amyotrophic lateral sclerosis (ALS) have a different functional brain network than healthy individuals, and that difference appears to be strongly associated with disability, according to new research. This finding supports previous research suggesting that monitoring a patient’s brain for changes in its neuronal network can aid in evaluating ALS disability and likely disease progression. The study,…

The molecular steps taken to turn immature stem cells into working motor neurons were seen in new research, potentially furthering cell therapies to treat neurological disorders like amyotrophic lateral sclerosis (ALS) by teaching scientists more about this complex process. The study, “A Multi-Step Transcriptional And Chromatin State Cascade Underlies Motor Neuron Programming From Embryonic Stem Cells,” was published…

BrainStorm Cell Therapeutics recently presented data from its Phase 2 clinical trial, showing that the company’s NurOwn stem cells technology may halt disease progression in patients with amyotrophic lateral sclerosis (ALS). The data were presented at the 27th International Symposium on ALS/MND in Dublin, Ireland. The multi-center, randomized, double blind, placebo-controlled,…